drugset / Trial / NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Phase 1
Completed
19 enrolled
Massachusetts General Hospital
National Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating a drug called carfilzomib used in combination with another drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma (NHL).
Timeline
- Start
- 2014-10
- Primary completion
- 2017-03
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Belinostat | Small molecule | 900 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | Intravenous |